DESOWEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DESOWEN (DESOWEN).
Desonide is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
| Metabolism | Desonide is primarily metabolized in the liver via ester hydrolysis to inactive metabolites. Minor CYP450 involvement; exact enzymes not well characterized. |
| Excretion | Primarily renal (approximately 70-80% as metabolites, <5% unchanged) after topical application, with minimal biliary/fecal elimination (<10%). |
| Half-life | The terminal elimination half-life of desonide (active metabolite of desowen) is approximately 2-4 hours, but the pharmacodynamic half-life (skin blanching) extends to 12-24 hours due to cutaneous retention. |
| Protein binding | Desonide is approximately 80-90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | The apparent volume of distribution (Vd) after topical absorption is approximately 0.5-1.0 L/kg, indicating distribution into total body water. |
| Bioavailability | Topical bioavailability is highly dependent on skin condition; approximately 1-5% of the applied dose is absorbed through intact skin, increasing to up to 30-50% in damaged or occluded skin. |
| Onset of Action | Topical: Clinical improvement (reduction in erythema, pruritus) typically begins within 24-48 hours of application. |
| Duration of Action | Duration of effect lasts 12-24 hours after a single application, supporting once- or twice-daily dosing for maintenance of remission. |
| Action Class | Glucocorticoids |
| Brand Substitutes | Desostar 0.05% Cream, Desomod Cream, Desova Cream, Desomag Cream, Dermanide Cream |
Apply a thin film to affected skin areas twice daily. Maximum duration of continuous use is 2 weeks. Not for ophthalmic, oral, or intravaginal use.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Children ≥3 months: Apply a thin film to affected areas twice daily. Maximum continuous use: 2 weeks. Avoid use in diaper area unless directed by physician. Not recommended for children <3 months. |
| Geriatric use | Use with caution due to increased risk of skin atrophy and systemic absorption. Apply smallest amount for shortest duration necessary. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DESOWEN (DESOWEN).
| Breastfeeding | It is unknown if desonide is excreted in human milk. Systemic absorption after topical application is minimal, but caution is advised. M/P ratio not available. Use only if clearly needed; apply to smallest area for shortest duration, and avoid application to breast area to prevent infant exposure. |
| Teratogenic Risk | Desonide (Desowen) is a topical corticosteroid classified as FDA Pregnancy Category C. Systemic exposure after topical application is minimal but may increase with widespread use, occlusive dressings, or damaged skin. Animal studies have shown teratogenicity with topical corticosteroids, but no adequate human studies exist. Risk cannot be ruled out; use only if potential benefit justifies potential risk to the fetus. First trimester: avoid unless essential; second/third trimester: caution. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to desonide or any component of the formulation.","Untreated bacterial, fungal, or viral infections at the application site."]
| Precautions | ["Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, especially in children or with prolonged use.","Local adverse reactions include skin atrophy, telangiectasias, and striae.","Avoid use on infected lesions without appropriate antimicrobial therapy.","Not for ophthalmic or oral use."] |
| Food/Dietary | No known food interactions with topical desonide. Systemic absorption is minimal with proper topical use. |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring required for topical use. Monitor maternal skin for signs of infection, atrophy, or hypersensitivity. During prolonged or extensive use, monitor for signs of HPA axis suppression in the mother (fatigue, hypotension, hypoglycemia). |
| Fertility Effects | No human data available. In animal studies, topical corticosteroids have not shown adverse effects on fertility. Unlikely to affect fertility due to minimal systemic absorption. |
| Clinical Pearls |
| Desonide (Desowen) is a low-potency topical corticosteroid, classified as group VI. It is suitable for use on face, intertriginous areas, and in children due to low risk of atrophy. Apply sparingly; limit use to 2 weeks continuously. Avoid occlusive dressings unless directed. Not for ophthalmic use. |
| Patient Advice | Apply a thin layer to affected skin only, usually 2-4 times daily as directed. · Do not cover the area with bandages or wrappings unless instructed by your doctor. · Avoid contact with eyes, mouth, or open wounds. If contact occurs, rinse thoroughly. · Do not use for diaper rash or on broken skin without medical advice. · Report any signs of skin infection, thinning, or allergic reaction to your doctor. · Do not stop abruptly if used long-term; physician may need to taper use. |